Home > Oncology > ESMO 2020 > Gastrointestinal Cancers > Nivolumab plus chemotherapy: new standard for first-line treatment of gastric cancer?

Nivolumab plus chemotherapy: new standard for first-line treatment of gastric cancer?


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Conference
ESMO 2020
Both CheckMate-649 and ATTRACTION-4 showed a statistically significant improvement in progression-free survival (PFS) for nivolumab-based first-line treatment of advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/oesophageal adenocarcinoma (EAC) In recent years, nivolumab provided superior overall survival (OS) in heavily pretreated patients with GC/GEJC [1]. In addition, first-line treatment with nivolumab plus chemotherapy showed promising results in a phase 2 trial in patients with advanced/recurrent GC/GEJC [2]. In CheckMate 649, 1,581 patients were 1:1 randomised to receive either nivolumab (240 mg) plus chemotherapy (FOLFOX every 2 weeks or XELOX every 3 weeks) or chemotherapy alone. In patients with positive PD-L1 tumour expression (CPS ≥5) both PFS and OS were significantly improved in the nivolumab plus chemotherapy-arm versus chemotherapy alone [3]. Median OS was 14.4 versus 11.1 months (HR 0.71; P<0.0001) and OS rate a...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on